SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys is trending as retail investors rally behind the stock, driven by strong sentiment on social media platforms that frame the company as a prime short-squeeze candidate with solid long-term fundamentals. The community is actively debating whether current volume levels can sustain a parabolic move, with many users encouraging others to hold shares to squeeze short positions while others caution about the risks of a classic pump-and-dump dynamic.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense community debate as the stock hits multi-year lows, driven by concerns over its debt-fueled Bitcoin acquisition strategy and the stability of its preferred equity offerings. While some investors view the current price as a structural value opportunity to accumulate shares, a vocal segment of the community warns of ongoing shareholder dilution and potential risks to the company's long-term solvency.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is experiencing heightened activity as traders weigh new investments in autonomous vehicle technology, including a significant stake in robotaxi developer Nuro, against broader market volatility impacting growth stocks. The community remains divided, with many highlighting the stock's strong fundamentals and potential World Cup demand tailwinds while others express frustration over persistent technical weakness and skepticism toward high autonomous vehicle operational costs.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing significant volatility following its first post-IPO earnings release, which showed strong revenue growth but was accompanied by concerns over shrinking gross margins and upcoming insider share lockup expirations. While the company announced a major multi-year partnership with OpenAI, investors are heavily debating the sustainability of its valuation and the impact of potential insider selling pressure.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors brace for high-stakes earnings, with the community intensely debating whether the stock's parabolic growth is fully priced in or if the structural memory super-cycle justifies further upside. Sentiment is sharply divided between bulls expecting a blowout report to trigger a massive breakout and bears positioning for a post-earnings sell-off due to extreme volatility and concerns over unsustainable capital expenditures.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is trending as investors debate whether the stock is a cyclical mortgage play hindered by rising interest rates or a long-term AI-driven housing platform poised for a structural repricing. Community sentiment remains deeply divided, with some traders focused on short-term price volatility and potential institutional accumulation, while others express frustration over stagnant performance compared to IPO levels and ongoing market uncertainty regarding housing policy.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors speculate on potential index-fund buying ahead of the upcoming Russell 1000 reconstitution. The community is actively discussing the company's prospects for global expansion, anticipated clinical data, and the ongoing battle with significant short interest.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is facing significant investor frustration as the stock continues to struggle, driven by recent clinical trial setbacks and the upcoming departure of its CFO. While some investors see the high dividend yield as a compelling reason to accumulate shares, the community remains divided over the company's long-term leadership and the effectiveness of its oncology and weight-loss pipelines.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is surging as investors react to a major new partnership with Tesla and Renew Home, which aims to leverage millions of residential solar and battery systems to create a massive virtual power plant for data centers and AI energy needs. The community is actively debating whether this infrastructure-light model will trigger a long-term valuation re-rating or if the stock remains susceptible to volatility and broader sector headwinds.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant downward pressure and intense community frustration as the stock faces a sharp correction, with investors debating whether the selloff is an algorithmic overreaction or a fundamental response to concerns over debt and capital expenditure. Despite strong backlog figures and long-term bullish sentiment from some, many participants are calling for management changes and expressing disbelief at the persistent disconnect between the company's enterprise cloud growth and its recent price performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Companys Board of...

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

Arcus Biosciences In Clinical Trial Collaboration With Bristol Myers Squibb For Renal Cell Carcinoma

(RTTNews) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Wednesday a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY...

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PDL1/VEGFA Bispecific Immunomodulator to Treat Kidney Cancer

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with...

Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the...

Arcus Biosciences (NYSE:RCUS) Issues Earnings Results

Arcus Biosciences (NYSE:RCUS - Get Free Report) posted its earnings results on Tuesday. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus...

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -10.87% and +21.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and...

Arcus Biosciences (NYSE:RCUS) Rating Increased to Strong-Buy at Truist Financial

Truist Financial raised Arcus Biosciences to a "strong-buy" rating in a report on Monday...

Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?

Eton Pharmaceuticals (ETON) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Arcus Biosciences Inc

Why Did Arcus Biosciences Stock Slump 10% Today?

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$29.55
Prev Close	$28.18
Open	$28.74
Dividend Yield	0.00%
50-Day Moving Average	$24.46
Beta	1.52
Avg. Volume	952,066.36
PE Ratio	-8.85

52-Week High	$28.72
52-Week Low	$7.91
Market Capitalization	$3.54B
EPS (Annual)	-$3.29
Price to Book	6.75
Revenue Per Employee	$410,981.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

RCUSArcus Biosciences Inc

Latest RCUS News